Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Aumolertinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized aumolertinib as a monotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution variants.
This statement is based on a regulatory approval from the European Medicines Agency:
Aumseqa as monotherapy is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution mutations.